Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 1 – Immunotherapy of cancer

4739 - Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumor responses in patients with NY-ESO-1 expressing solid tumors.


28 Sep 2019


Poster Discussion 1 – Immunotherapy of cancer


Marcus Butler


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


M.O. Butler1, V. Sotov2, S. Saibil1, L. Bonilla1, S. Boross-Harmer2, M. Fyrsta2, D. Gray2, M. Nelles2, M. Le2, D. Lemiashkova2, D. Liu2, A.G. Sacher1, A. Trang2, K. Vakili2, B. Van As2, E. Scheid2, L. Nguyen2, S. Takahashi3, S. Tanaka3, N. Hirano2

Author affiliations

  • 1 Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA
  • 2 Tumor Immunotherapy Program, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA
  • 3 Clinical Development &strategy Division 1, Takara Bio, Inc, Kusatsu/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4739


We are conducting a single site, investigator-initiated Phase Ib study with TBI-1301 where autologous T cells are genetically engineered to express a high affinity NY-ESO-1-specific T cell receptor (TCR) and adoptively transferred to HLA-A*02:01+ or A*02:06+ patients with NY-ESO-1+ solid tumors. Point-of-care manufacturing was performed where peripheral lymphocytes are transduced with the MS3II-NY-ESO1-SiTCR retroviral vector, which encodes an exogenous NY-ESO-1 specific TCR and siRNAs targeting endogenous TCR.


Patients underwent modest lymphodepletion with cyclophosphamide (750 mg/m2 on day -3 and -2) followed by a planned infusion of 5x10^9 manufactured TBI-1301 cells on day 0. All patients underwent immune assessment of PBMC by flow cytometry analysis to monitor persistence and phenotype changes of the infused T cells using NY-ESO1-specific pentamer and the following antibodies: CD45RA, HLA-DR, CD27, CD57, CCR7, PD-1, 4-1BB, CD28, TIGIT, CTLA-4, CD103, LAG3, Ki-67, CD25, CD127, and FoxP3.


9 patients (1 endometrial cancer, 1 ovarian cancer, 4 synovial sarcoma, 3 melanoma) were infused with TBI-1301 at the target cell dose with the exception of one synovial sarcoma patient who received 2.1x10^9 TBI-1301 cells. TBI-1301 was well tolerated, and there were no dose limiting toxicities. CRS grade 1-2 was experienced by 5 patients, with two patients requiring tocilizumab. RECIST best overall responses to date are as follows: 2 PR, 5 SD, 1 PD, and 1 pending. Three patients showed detectable levels of NY-ESO1-specific T cells in the periphery for greater than 100 days post infusion. Biomarker analysis of persisting NY-ESO-1 pentamer+ TBI-1301 cells in the peripheral blood showed increased expression of CD27, PD-1 and TIGIT. Additionally, patients with a PR showed significantly higher numbers of NY-ESO-1 CD8+ T cells costaining with CD45RA and CCR7.


ACT with TBI-1301 cells is safe and clinically active. Results provided here confirm long-term persistence of gene-engineered T cells with higher frequencies of CD45RA+ CCR7+ CD8+ T cells in responding patients. Detailed biomarker analysis of persisting TBI-1301 cells will be presented.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Princess Margaret Cancer Foundation, Takara Bio, Inc.


M.O. Butler: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Pfizer; Advisory / Consultancy: GSK; Advisory / Consultancy: Immunocore; Advisory / Consultancy: Adaptimmune; Research grant / Funding (institution): Takara Bio. A.G. Sacher: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca/MedImmune; Advisory / Consultancy: Bayer; Honoraria (self), Travel / Accommodation / Expenses: Genentech/Roche; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Gritstone Oncology; Honoraria (self): Merck. S. Takahashi: Full / Part-time employment: Takara Bio, Inc. N. Hirano: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Licensing / Royalties: Takara Bio, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.